| ［1］ |
de Jong E, Lammerts M, Genders RE, et al. Update of advanced cutaneous squamous cell carcinoma［J］. J Eur Acad Dermatol Venereol, 2022,36（Suppl 1）:6⁃10. doi: 10.1111/jdv. 17728.
|
| ［2］ |
Genders RE, Weijns ME, Dekkers OM, et al. Metastasis of cutaneous squamous cell carcinoma in organ transplant recipients and the immunocompetent population: is there a difference? A systematic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2019,33（5）:828⁃841. doi: 10.1111/jdv.15396.
|
| ［3］ |
Guba M, Graeb C, Jauch KW, et al. Pro⁃ and anti⁃cancer effects of immunosuppressive agents used in organ transplantation［J］. Transplantation, 2004,77（12）:1777⁃1782. doi: 10.1097/01.tp. 0000120181.89206.54.
|
| ［4］ |
Brougham ND, Tan ST. The incidence and risk factors of metastasis for cutaneous squamous cell carcinoma⁃⁃implications on the T⁃classification system［J］. J Surg Oncol, 2014,110（7）:876⁃882. doi: 10.1002/jso.23731.
|
| ［5］ |
Sunkara RR, Sarate RM, Setia P, et al. SFRP1 in skin tumor initiation and cancer stem cell regulation with potential implications in epithelial cancers［J］. Stem Cell Reports, 2020,14（2）:271⁃284. doi: 10.1016/j.stemcr.2019.12.006.
|
| ［6］ |
Parsons MJ, Tammela T, Dow LE. WNT as a driver and dependency in cancer［J］. Cancer Discov, 2021,11（10）:2413⁃2429. doi: 10.1158/2159⁃8290.CD⁃21⁃0190.
|
| ［7］ |
Zimmerli D, Cecconi V, Valenta T, et al. WNT ligands control initiation and progression of human papillomavirus⁃driven squamous cell carcinoma［J］. Oncogene, 2018,37（27）:3753⁃3762. doi: 10.1038/s41388⁃018⁃0244⁃x.
|
| ［8］ |
Dayal J, Mason SM, Salas⁃Alanis JC, et al. Heterogeneous addiction to transforming growth factor⁃beta signalling in recessive dystrophic epidermolysis bullosa⁃associated cutaneous squamous cell carcinoma［J］. Br J Dermatol, 2021,184（4）:697⁃708. doi: 10.1111/bjd.19421.
|
| ［9］ |
Li L, Li F, Xia Y, et al. UVB induces cutaneous squamous cell carcinoma progression by de novo ID4 methylation via methylation regulating enzymes［J］. EBioMedicine, 2020,57:102835. doi: 10. 1016/j.ebiom.2020.102835.
|
| ［10］ |
Ke Y, Wang XJ. TGFβ signaling in photoaging and UV⁃induced skin cancer［J］. J Invest Dermatol, 2021,141（4S）:1104⁃1110. doi: 10.1016/j.jid.2020.11.007.
|
| ［11］ |
Zhang J, Jiang H, Xu D, et al. DNA⁃PKcs mediates an epithelial⁃mesenchymal transition process promoting cutaneous squamous cell carcinoma invasion and metastasis by targeting the TGF⁃β1/Smad signaling pathway［J］. Onco Targets Ther, 2019,12:9395⁃9405. doi: 10.2147/OTT.S205017.
|
| ［12］ |
Wang H, Li H, Yan Q, et al. Serum matrix metalloproteinase⁃13 as a diagnostic biomarker for cutaneous squamous cell carcinoma［J］. BMC Cancer, 2021,21（1）:816. doi: 10.1186/s12885⁃021⁃08566⁃1.
|
| ［13］ |
Taniguchi S, Elhance A, Van Duzer A, et al. Tumor⁃initiating cells establish an IL⁃33⁃TGF⁃β niche signaling loop to promote cancer progression［J］. Science, 2020,369（6501）:eaay1813 ［pii］. doi: 10.1126/science.aay1813.
|
| ［14］ |
Peng D, Fu M, Wang M, et al. Targeting TGF⁃β signal transduction for fibrosis and cancer therapy［J］. Mol Cancer, 2022,21（1）:104. doi: 10.1186/s12943⁃022⁃01569⁃x.
|
| ［15］ |
Mercurio L, Albanesi C, Madonna S. Recent updates on the involvement of PI3K/AKT/mTOR molecular cascade in the pathogenesis of hyperproliferative skin disorders［J］. Front Med （Lausanne）, 2021,8:665647. doi: 10.3389/fmed.2021.665647.
|
| ［16］ |
Hafner C, Landthaler M, Vogt T. Activation of the PI3K/AKT signalling pathway in non⁃melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations［J］. Exp Dermatol, 2010,19（8）:e222⁃227. doi: 10.1111/j.1600⁃0625. 2009.01056.x.
|
| ［17］ |
Thakur MA, Khandelwal AR, Gu X, et al. Inhibition of fibroblast growth factor receptor attenuates UVB⁃induced skin carcino⁃genesis［J］. J Invest Dermatol, 2022,142（11）:2873⁃2884.e7. doi: 10.1016/j.jid.2022.03.036.
|
| ［18］ |
Yu H, Lin L, Zhang Z, et al. Targeting NF⁃κB pathway for the therapy of diseases: mechanism and clinical study［J］. Signal Transduct Target Ther, 2020,5（1）:209. doi: 10.1038/s41392⁃020⁃00312⁃6.
|
| ［19］ |
Mirzaei S, Saghari S, Bassiri F, et al. NF⁃κB as a regulator of cancer metastasis and therapy response: a focus on epithelial⁃mesenchymal transition［J］. J Cell Physiol, 2022,237（7）:2770⁃2795. doi: 10.1002/jcp.30759.
|
| ［20］ |
Ma X, Wu D, Zhang X, et al. microRNA⁃214 prevents traits of cutaneous squamous cell carcinoma via VEGFA and Bcl⁃2［J］. Technol Cancer Res Treat, 2020,19:15330338 20980098. doi: 10.1177/1533033820980098.
|
| ［21］ |
Neagu M, Constantin C, Cretoiu SM, et al. miRNAs in the diagnosis and prognosis of skin cancer［J］. Front Cell Dev Biol, 2020,8:71. doi: 10.3389/fcell.2020.00071.
|
| ［22］ |
Gong ZH, Zhou F, Shi C, et al. miRNA⁃221 promotes cutaneous squamous cell carcinoma progression by targeting PTEN［J］. Cell Mol Biol Lett, 2019,24:9. doi: 10.1186/s11658⁃018⁃0131⁃z.
|
| ［23］ |
Zhou B, Lin W, Long Y, et al. Notch signaling pathway: architecture, disease, and therapeutics［J］. Signal Transduct Target Ther, 2022,7（1）:95. doi: 10.1038/s41392⁃022⁃00934⁃y.
|
| ［24］ |
Di Nardo L, Pellegrini C, Di Stefani A, et al. Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies［J］. J Eur Acad Dermatol Venereol, 2020,34（5）:932⁃941. doi: 10.1111/jdv.16098.
|
| ［25］ |
Bednarski IA, Ciążyńska M, Wódz K, et al. Hippo signaling pathway as a new potential target in non⁃melanoma skin cancers: a narrative review［J］. Life （Basel）, 2021,11（7）:680. doi: 10. 3390/life11070680.
|
